Analysts Issue Forecasts for NextCure FY2030 Earnings

NextCure, Inc. (NASDAQ:NXTC) – Equities researchers at HC Wainwright issued their FY2030 earnings estimates for shares of NextCure in a research report issued to clients and investors on Wednesday, July 15th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($0.18) for the year. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for NextCure’s current full-year earnings is ($7.89) per share.

NextCure (NASDAQ:NXTC) last posted its earnings results on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.10) by $0.23.

Several other analysts have also recently weighed in on NXTC. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 11th. Weiss Ratings lowered NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 7th. Finally, Wall Street Zen lowered NextCure from a “hold” rating to a “sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $19.00.

NextCure Stock Performance

NXTC stock opened at $5.99 on Thursday. The company has a fifty day moving average price of $4.43 and a 200-day moving average price of $9.30. The company has a market capitalization of $21.62 million, a P/E ratio of -0.35 and a beta of 1.42. NextCure has a 52-week low of $1.55 and a 52-week high of $15.74.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its stake in shares of NextCure by 80.0% in the 1st quarter. Renaissance Technologies LLC now owns 60,534 shares of the company’s stock valued at $647,000 after purchasing an additional 26,900 shares during the last quarter. Ikarian Capital LLC purchased a new stake in shares of NextCure in the fourth quarter worth approximately $3,382,000. Squadron Capital Management LLC purchased a new stake in shares of NextCure in the fourth quarter worth approximately $3,363,000. Millennium Management LLC bought a new position in shares of NextCure in the fourth quarter valued at approximately $185,000. Finally, Boothbay Fund Management LLC bought a new position in shares of NextCure in the fourth quarter valued at approximately $988,000. Institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.